+

Cookies on the Business Insider India website

Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.

Close
HomeQuizzoneWhatsappShare Flash Reads
 

Wall Street is going to listen in to Bill Ackman defend his Valeant investment

Oct 30, 2015, 03:06 IST

Bloomberg via Getty Images

Billionaire activist investor Bill Ackman, founder of Pershing Square Capital, is hosting a conference call for investors on Friday morning to discuss his fund's investment in Valeant Pharmaceuticals.

Advertisement

The call will take place at 9 a.m. ET, with Ackman and other Pershing Square portfolio managers and analysts taking questions.

Since taking a position earlier this year, Pershing Square has likely lost more than $1.5 billion on paper on Valeant, the fund's largest stock holding.

Shares of the Canadian drug company have collapsed since Wednesday after the California-based short-selling firm Citron Research published a report asking whether Valeant was operating an Enron-like fraud.

Citron's report focuses on the company's relationship with Philidor, a specialty pharmacy that distributes prescription drugs for Valeant. Valeant is the only supplier to Philidor, and it also has an option to buy the company. On Wall Street, no one had really heard of Philidor until earlier this month.

Advertisement

Citron has accused Valeant of using Philidor, and an unknown number of specialty pharmacies like it, to generate fake invoices so it can book revenue for sales that never happened.

Valeant has categorically denied the allegations in the Citron report. The company hosted an all-hands call on Monday morning to address the allegations.

Valeant's share price has declined by more than 40% since the report came out.

Valeant's share price was last trading at around $99.91 per share in the after-hours session on Thursday after CVS and Express Scripts terminated their relationships with Philidor.

What's at stake?

Ackman's Pershing Square Capital Management owns 21,473,933 shares of Valeant, including 2 million shares Ackman bought during last Wednesday's sell-off.

Advertisement

Pershing Square is Valeant's third-largest shareholder. The stock is Ackman's largest investment. The losses have dragged down his fund's performance.

Pershing Square Holdings, the fund's pubicly traded vehicle, is down 15.9% this year through Tuesday, October 27.

Ackman first disclosed his position in Valeant on March 17, when the share price was $200 per share. At that share price, the position was worth $3.9 billion. With his added shares from last week, Ackman's position is worth $2.14 billion. That would represent a loss of around $1.76 billion.

We're going to be covering the call live. Be sure to follow us for all the updates.

NOW WATCH: Homeless man turned billionaire shares the secret to the American dream

Please enable Javascript to watch this video
You are subscribed to notifications!
Looks like you've blocked notifications!
Next Article